Human monoclonal IgG1 antibody, binds and blocks IL-17A
Medium to severe plaque psoriasis, approved from 18 years of age (PASI>10/BSA>10/DLQI>10, according to Swiss S1 guidelines). Available as syringe or PEN
Treatment of adult patients with severe psoriasis (Def. in USZ and Swiss S1 Guideline): PASI > 10 or BSA > 10 and/or DLQI > 10) in which UVB and PUVA or one of the following three systemic therapies (ciclosporin, methotrexate, acitretin) have not shown therapeutic success. In iximab, additional failure of another TNF blocker approved for psoriasis
Pre-filled syringe, pen
Blood count, liver enzymes, creatinine, U status, pregnancy test in urine, CRP/ ESR. Screening for HBV, HCV, HIV and tuberculosis including Rx thorax.
300 mg in week 0, 1, 2, 3, 4, repeated every month (approx. 4 weeks). Attention, two syringes are required for 300 mg.
2 - 3 weeks
Week 12: 75 - 87 % Week 16: 86 % (300 mg)
Week 12: 59.2 % Week 16: 69.8 % (300 mg)
> 90 % achieve PASI 75 again after 12 - 16 weeks of re-treatment
PASI, (use PrecisePASI for greater accuracy once PASI < 10), DLQI after 12 and 24 weeks
Absolute contraindications: Active tuberculosis or acute, severe infections, live vaccinations, active chronic hepatitis B, pregnancy and breastfeeding. Relative contraindications: Crohn's disease (engombolic monitoring). Malignant diseases (except BCC and lymphoproliferative diseases).
We and our partners are using technologies like cookies and process personal data like the IP-address or browser information in order to personalize the advertising that you see. This helps us to show you more relevant ads and improves your internet experience. We also use it in order to measure results or align our website content. Because we value your privacy, we are herewith asking for your permission to use these technologies. You can always change/withdraw your consent later.